Evaluation of vitamin K2 (menatetrenone) administration with hormone replacement therapy on prevention of osteoporosis in climateric women

Present study was performed to elucidate whether vitamin K-2 administration with HRT was more effective for the prevention of the osteoporosis in the climacteric women. Fifty-eight menopausal women without any complications w ere subjected. They were divided into two groups; A: Hormone replacement th erapy (HRT; Premarin 0.625mg+Provera 2.5mg/day) only, 35 cases, and B: HRTvitamin K-2 (45mg/day), 23 cases. And the bone mineral density (BMD) values of L2-4 (before, 6 and 12 months after treatment) were evaluated by DXA me thod (QDR-2000, Hologic Co.). There was no significant change in the absolu te BMD values between group A and B (before: 0.751+/-0.087 vs. 0.748+/-0.09 1, 6 months after: 0.761+/-0.095 vs. 0.770+/-0.088, 12 months after: 0.781/-0.094 vs. 0.790+/-0.096 g/cm(2)). However, a significant increase was obs erved in the group B on the percent change values of the bone mass; 6 month s after: 1.56+/-1.24 vs. 2.95+/-1.68% (p< 0.02), 12 months after: 3.95+/-2. 16 vs. 5.62+/-2.57% (p<0.01). From these results, it was concluded that Vit amin K-2 administration combined with HRT is more effective for the prevent ion of the osteoporosis through the mechanism of its promotive action for t he osteogenesis.